Group II metabotropic glutamate receptors as targets for novel antipsychotic drugs
Schizophrenia is a chronic psychiatric disorder which substantially impairs patients’ quality of life. Despite the extensive research in this field, the pathophysiology and aetiology of schizophrenia remain unknown. Different neurotransmitter systems and functional networks have been found to be aff...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2016-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00130/full |
| _version_ | 1818856233659006976 |
|---|---|
| author | Carolina eMuguruza Javier eMeana Luis F Callado |
| author_facet | Carolina eMuguruza Javier eMeana Luis F Callado |
| author_sort | Carolina eMuguruza |
| collection | DOAJ |
| description | Schizophrenia is a chronic psychiatric disorder which substantially impairs patients’ quality of life. Despite the extensive research in this field, the pathophysiology and aetiology of schizophrenia remain unknown. Different neurotransmitter systems and functional networks have been found to be affected in the brain of patients with schizophrenia. In this context, postmortem brain studies as well as genetic assays have suggested alterations in Group II metabotropic glutamate receptors (mGluRs) in schizophrenia.Despite many years of drug research, several needs in the treatment of schizophrenia have not been addressed sufficiently. In fact, only 5-10% of patients with schizophrenia successfully achieve a full recovery after treatment. In recent years mGluRs have turned up as novel targets for the design of new antipsychotic medications for schizophrenia. Concretely, Group II mGluRs are of particular interest due to their regulatory role in neurotransmission modulating glutamatergic activity in brain synapses. Preclinical studies have demonstrated that orthosteric Group II mGluR agonists exhibit antipsychotic-like properties in animal models of schizophrenia. However, when these compounds have been tested in human clinical studies with schizophrenic patients results have been inconclusive. Nevertheless, it has been recently suggested that this apparent lack of efficacy in schizophrenic patients may be related to previous exposure to atypical antipsychotics. Moreover, the role of the functional heterocomplex formed by 5-HT2A and mGlu2 receptors in the clinical response to Group II mGluR agonists is currently under study. |
| first_indexed | 2024-12-19T08:21:15Z |
| format | Article |
| id | doaj.art-9b25e00d1d9f4f6384ff6b6a03893b24 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-19T08:21:15Z |
| publishDate | 2016-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-9b25e00d1d9f4f6384ff6b6a03893b242022-12-21T20:29:23ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122016-05-01710.3389/fphar.2016.00130195603Group II metabotropic glutamate receptors as targets for novel antipsychotic drugsCarolina eMuguruza0Javier eMeana1Luis F Callado2University of the Basque CountryUniversity of the Basque CountryUniversity of the Basque CountrySchizophrenia is a chronic psychiatric disorder which substantially impairs patients’ quality of life. Despite the extensive research in this field, the pathophysiology and aetiology of schizophrenia remain unknown. Different neurotransmitter systems and functional networks have been found to be affected in the brain of patients with schizophrenia. In this context, postmortem brain studies as well as genetic assays have suggested alterations in Group II metabotropic glutamate receptors (mGluRs) in schizophrenia.Despite many years of drug research, several needs in the treatment of schizophrenia have not been addressed sufficiently. In fact, only 5-10% of patients with schizophrenia successfully achieve a full recovery after treatment. In recent years mGluRs have turned up as novel targets for the design of new antipsychotic medications for schizophrenia. Concretely, Group II mGluRs are of particular interest due to their regulatory role in neurotransmission modulating glutamatergic activity in brain synapses. Preclinical studies have demonstrated that orthosteric Group II mGluR agonists exhibit antipsychotic-like properties in animal models of schizophrenia. However, when these compounds have been tested in human clinical studies with schizophrenic patients results have been inconclusive. Nevertheless, it has been recently suggested that this apparent lack of efficacy in schizophrenic patients may be related to previous exposure to atypical antipsychotics. Moreover, the role of the functional heterocomplex formed by 5-HT2A and mGlu2 receptors in the clinical response to Group II mGluR agonists is currently under study.http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00130/fullSchizophreniaGlutamatehuman brainantipsychoticmGlu2R receptors |
| spellingShingle | Carolina eMuguruza Javier eMeana Luis F Callado Group II metabotropic glutamate receptors as targets for novel antipsychotic drugs Frontiers in Pharmacology Schizophrenia Glutamate human brain antipsychotic mGlu2R receptors |
| title | Group II metabotropic glutamate receptors as targets for novel antipsychotic drugs |
| title_full | Group II metabotropic glutamate receptors as targets for novel antipsychotic drugs |
| title_fullStr | Group II metabotropic glutamate receptors as targets for novel antipsychotic drugs |
| title_full_unstemmed | Group II metabotropic glutamate receptors as targets for novel antipsychotic drugs |
| title_short | Group II metabotropic glutamate receptors as targets for novel antipsychotic drugs |
| title_sort | group ii metabotropic glutamate receptors as targets for novel antipsychotic drugs |
| topic | Schizophrenia Glutamate human brain antipsychotic mGlu2R receptors |
| url | http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00130/full |
| work_keys_str_mv | AT carolinaemuguruza groupiimetabotropicglutamatereceptorsastargetsfornovelantipsychoticdrugs AT javieremeana groupiimetabotropicglutamatereceptorsastargetsfornovelantipsychoticdrugs AT luisfcallado groupiimetabotropicglutamatereceptorsastargetsfornovelantipsychoticdrugs |